- Home
- EWTX
as 11-21-2024 4:00pm EST
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 3.3B | IPO Year: | 2021 |
| Target Price: | $40.40 | AVG Volume (30 days): | 679.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.46 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.93 - $38.12 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Edgewise Therapeutics Inc. (EWTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Carruthers R Michael | EWTX | Chief Financial Officer | Sep 20 '24 | Sell | $28.58 | 125,092 | $3,573,979.93 | 31,864 | |
| MOORE JOHN R | EWTX | General Counsel | Sep 20 '24 | Sell | $28.00 | 70,922 | $1,996,574.40 | 3,252 | |
| Donovan Joanne M. | EWTX | CMO | Sep 20 '24 | Sell | $28.29 | 7,162 | $202,602.95 | 14,538 | |
| Derakhshan Behrad | EWTX | Chief Business Officer | Sep 20 '24 | Sell | $29.03 | 42,068 | $1,221,133.08 | 15,121 | |
| Russell Alan J | EWTX | Chief Scientific Officer | Sep 20 '24 | Sell | $28.88 | 75,000 | $2,120,101.20 | 12,719 |
Latest Edgewise Therapeutics Inc. News
EWTX Breaking Stock News: Dive into EWTX Ticker-Specific Updates for Smart Investing
MT Newswires
13 days ago
RBC Capital Adjusts Edgewise Therapeutics Price Target to $44 From $42, Maintains Outperform, Speculative Risk Rating
Business Wire
14 days ago
Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Insider Monkey
a month ago
Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now
Business Wire
2 months ago
Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society
BioPharma Dive
2 months ago
Novo sinks on obesity drug results; Sanofi reveals anticipated MS data
MT Newswires
2 months ago
RBC Raises Price Target on Edgewise Therapeutics to $42 From $32, Keeps Outperform, Speculative Risk
Zacks
2 months ago
Company News for Sep 20, 2024
Clinical Trials Arena
2 months ago
Edgewise’s EDG-7500 shows benefit in two obstructive HCM trials
Compare EWTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EWTX Edgewise Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.